GlaxoSmithKline: HIV Drug Apretude Approved in US by FDA
21 December 2021 - 06:48PM
Dow Jones News
By Sabela Ojea
GlaxoSmithKline PLC said Tuesday that its Apretude drug, which
reduces the risk of HIV acquisition, has been approved by the U.S.
Food and Drug Administration.
The British pharma major said that Apretude was developed by
ViiV Healthcare, the specialist HIV company majority owned by
GSK.
"Apretude is the first and only pre-exposure prophylaxis option
to reduce the risk of sexually acquired HIV," the FTSE 100 listed
company said.
The drug was approved for use by adults and adolescents weighing
at least 35 kilograms, the company said.
"With Apretude, people can reduce the risk of acquiring HIV with
as few as six injections a year," said Deborah Waterhouse, Chief
Executive of ViiV Healthcare.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 21, 2021 02:33 ET (07:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024